By modulating chromatin structure and restoring the expression of silenced genes, HDAC inhibitors can enhance chemosensitivity, particularly in relapsed, refractory, or high-risk AML cases (Maiso et al., 2009). The gene discussed is HDAC9; the disease is acute myeloid leukemia.